ArticleAnnals of translational medicine2022
The effects of photobiomodulation therapy on inflammatory mediators, immune infiltration, and angiogenesis in a mouse model of rosacea.
Article in Annals of translational medicine, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
8 citing papers in PubMed.
- Review
- Simple Custom Led Panel increases Adipogenic Differentiation of Adipose-Derived Mesenchymal Stem Cells through Photobiomodulation.Journal of stem cells & regenerative medicine · 2026Article
- Virtual screening identifies specnuezhenide as a potential therapeutic agent for rosacea via KLK5/TLR4/NF-κB pathway inhibition and metabolic modulation.Frontiers in immunology · 2026Article
- Melanogenesis inhibition and anti-inflammation is essential for pigment-clearance in melasma treated by low-fluence Q-switched nd: YAG 1064 nm laser.Lasers in medical science · 2025Article
- Oral tranexamic acid, low-fluence intense pulsed light, and glycolic acid for the treatment of mixed melasma: An observational study.Medicine · 2025Observational
- Could photobiomodulation be used for treatment of rosacea?Lasers in medical science · 2025Review
- Transcranial photobiomodulation for neurodevelopmental disorders: a narrative review.Photochemical & photobiological sciences : Official journal of the European Photochemistry Association and the European Society for Photobiology · 2024Review
- Unleashing light's healing power: an overview of photobiomodulation for Alzheimer's treatment.Future science OA · 2024Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Rosacea is a chronic skin disorder with increasing prevalence and challenging management. Photobiomodulation therapy (PBMT) may be a promising adjuvant treatment for rosacea. Methods: This study investigated the efficacy of PBMT for the treatment of rosacea lesions in a well-established mouse model using a combination of wavelengths at 590 and 830 nm. Female BALB/c mice were randomized into three groups, namely, a negative control (NC) group, a model control (MC) group, and a PBMT group. Mice were injected with LL-37 or normal saline for construction of the model and NCs, respectively. Mice in the PBMT group were administered PBMT at wavelengths of 590 nm (25 mW) and 830 nm (50 mW). The severity of erythema, inflammatory cell counts, the expression of key inflammatory mediators, and the degree of angiogenesis and immune cell infiltration of the skin lesions were evaluated by hematoxylin and eosin (H&E) staining, immunohistochemistry, and immunofluorescence staining. Results: PBMT significantly decreased the erythema scores and inflammatory cell infiltration of rosacea lesions in mice. Further studies revealed that PBMT downregulated the increased expression of inflammatory mediators (S100A9 and p65) and angiogenesis markers (CD31), and attenuated the dysregulation of immune cell infiltration [including neutrophils, regulatory T cells (Treg cells), γδ T cells, and macrophages] in mice with rosacea. Conclusions: This investigation suggested that PBMT can improve the rosacea condition by regulating key inflammatory mediators and dysregulating immune infiltration and angiogenesis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.